Kaiser Permanente Clinical Trials Tool Includes Cost-Effectiveness Modeling
This article was originally published in The Pink Sheet Daily
Executive Summary
The “Archimedes” trial results simulator would allow third-party payors to predict the amount of time before a new drug saves money. Kaiser is spending $17 mil. to develop the model, which could be available at a “non-profit” cost in three years.
You may also be interested in...
FDA To Adopt Cost-Effectiveness Role? Congress May Revisit Issue, Crawford Says
Medicare reform will link FDA more closely with CMS, which could necessitate FDA becoming more economically aware of approval decisions, Acting Commissioner Crawford says. FDAer envisions a relationship with CMS that is akin to a merger.
Biotech Companies Wary Of CMS Plans For Cost-Effectiveness Research
CMS Administrator nominee McClellan is expected to "pick up and continue" where former Administrator Scully left off in controlling drug prices, Ligand marketing exec Erwin says at BIO conference.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.